Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
The ever-worsening mental health crisis
Our aim is to focus on cutting-edge pragmatic Real-World Evidence (RWE) Studies to generate clinically meaningful data and physician experience faster, unlocking the true potential of these transformational therapies sooner.
We believe it’s the best way to ensure rapid, safe and appropriate access to reimbursed psilocybin therapy.
Driving positive mental health change
Psilocybin-based medicines will change the way mental health is treated, and as a result, we believe the human experience as a whole will improve.
Current mental health treatments are decades old, relatively ineffective and can come with severe side effects. New approaches to antidepressants have failed, and major pharma has abandoned R&D.
1 Billion People Suffer Worldwide
from anxiety and depression disorders worldwide [1]
Costs $1 Trillion Globally /yr
depression and anxiety, cost the global economy $1 trillion each year [1]
17m Anxiety & Depression Sufferers, UK
FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.
Psychotherapy in combination with KRN-101
Psilocybin therapy is a paradigm shift away from the traditional approaches such as antidepressants. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.
Leading academics are demonstrating success with psilocybin as well as other psychoactive psychedelic medicines as therapy for treatment-resistant depression, anxiety, drug addiction and much more.
Neuroscience
KRN-101
Psychological
Support
FDA Breakthrough Designation
FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.
Legally Accepted Therapeutic Use
FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.
Continued Success for Cancer Related Distress
FDA has granted three breakthrough therapy designations. One for MDMA and two psilocybin.
Preparation
In these first preparation sessions, an Albert Labs therapist will get to know you closely and form a trusting relationship. The focus will be on establishing a therapeutic alliance between the therapist and participant.
During preparation, the therapist aims to build the participant’s capacity to navigate distressing experiences through self-directed enquiry and experiential processing. Practising this approach during preparation helps prepare the participant to engage with their experiences in the psilocybin session.
Dosing session
During the psilocybin session, the focus is on facilitating a meaningful experience. Patients listen to crafted music playlists and wear an eye mask. This helps the participant to focus internally. The psilocybin experience typically lasts 6-8 hours, and the participant is encouraged to maintain a courageous, trusting and open attitude in order to move “in and through” the full range of internal experiences. Albert Lab’s therapists maintain the same attitudes of openness and interest toward participants.
Integration
The therapeutic focus of integration is to reflect on the experience and generate insights following the psilocybin session. Participants are encouraged to describe and connect with the range of emotional, cognitive and physical experiences of the psilocybin session and relate them to their personal narratives. The integration process will generally unfold over time as the participant begins to implement changes in their life based on the experiences and insights of their psilocybin session.
– November 30, 2016
1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.
– November 30, 2016
2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.
– September 6, 2010
3. Psilocybin treatment for anxiety in patients with advanced-stage cancer
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.